血清降钙素原和C反应蛋白联合检测指导肺部疾病患者抗菌药物应用的临床意义

摘要

目的：探讨血清降钙素原(PCT)与 C 反应蛋白(CRP)联合检测对肺部疾病患者抗菌药物临床应用的指导意义。方法选取2012年10月至2014年10月肺部疾病患者130例，随机分为观察组与对照组，各65例。观察组患者根据血清 PCT 与CRP 水平确定是否选用抗菌药物，对照组患者根据白细胞计数进行确定。比较治疗后两组患者的抗菌药物应用情况、临床治疗效果及患者住院时间等观察指标。结果观察组患者抗菌药物治疗时间[(8.6±0.4)d]少于对照组[(16.2±2.3)d]，差异有统计学意义(P <0.05)。治疗后，两组患者白细胞计数、肺功能状态评分、病情加重患者百分比及病死率比较差异均无统计学意义(P >0.05)；而与对照组比较，观察组患者住院时间缩短，二重感染率降低，差异均有统计学意义(P <0.05)。结论联合检测PCT 与 CRP 可指导肺部疾病患者合理选择抗菌药物进行治疗，能够有效防止二次感染，提高临床治疗效果。%Objective To explore the significance of combined detection of procalcitonin(PCT)and C reactive protein(CRP)for clinical use of antibacterial agents in patients with pulmonary disease.Methods 130 cases of patients with pulmonary disease,from October 2012 to October 2014,were selected and randomly dividend into the observation group and control group,65 cases in each group.In the observation group,the utilization of antibacterial agents was decided according to serum levels of PCT and CRP,while in the control group that was based on the white blood cell count.Observation indexes,such as utilization of antibacterial agents, curative efficiency,length of stay and so on,were compared between the two groups after treatment.Results The length of antibac-terial agents use in the observation group[(8.6±0.4)d]was longer than that in the control group[(1 6.2±2.3)d],had statistically significant difference(P <0.05 ).After treatment,there were no statistically significant differences in the white blood cell count, scores of pulmonary functional status,percentage of patients in aggravating stages and mortality between the two groups (P >0.05).While compared with the control group,the dual infection rate and length of stay decreased in the observation group,had sta-tistically significant difference(P <0.05).Conclusion Combined detection of PCT and CRP could guide the rational use of antibac-terial agents,effectively prevent the dual infection,and improve clinical curative effect.